prikaz prve stranice dokumenta Pregled farmakoekonomskih analiza terapije atopijskog dermatititsa
  Download
PDF 1.48 MB
master's thesis
Pregled farmakoekonomskih analiza terapije atopijskog dermatititsa
Zagreb: University of Zagreb, Faculty of Pharmacy and Biochemistry, 2019. urn:nbn:hr:163:525960
Matas, Elena
University of Zagreb
Faculty of Pharmacy and Biochemistry
Centre for applied pharmacy

Institutional repository: Repository of Faculty of Pharmacy and Biochemistry University of Zagreb

Cite this document

Matas, E. (2019). Pregled farmakoekonomskih analiza terapije atopijskog dermatititsa (Master's thesis). Zagreb: University of Zagreb, Faculty of Pharmacy and Biochemistry. Retrieved from https://urn.nsk.hr/urn:nbn:hr:163:525960

Matas, Elena. "Pregled farmakoekonomskih analiza terapije atopijskog dermatititsa." Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, 2019. https://urn.nsk.hr/urn:nbn:hr:163:525960

Matas, Elena. "Pregled farmakoekonomskih analiza terapije atopijskog dermatititsa." Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, 2019. https://urn.nsk.hr/urn:nbn:hr:163:525960

Matas, E. (2019). 'Pregled farmakoekonomskih analiza terapije atopijskog dermatititsa', Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, accessed 24 November 2024, https://urn.nsk.hr/urn:nbn:hr:163:525960

Matas E. Pregled farmakoekonomskih analiza terapije atopijskog dermatititsa [Master's thesis]. Zagreb: University of Zagreb, Faculty of Pharmacy and Biochemistry; 2019 [cited 2024 November 24] Available at: https://urn.nsk.hr/urn:nbn:hr:163:525960

E. Matas, "Pregled farmakoekonomskih analiza terapije atopijskog dermatititsa", Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, Zagreb, 2019. Available at: https://urn.nsk.hr/urn:nbn:hr:163:525960

Metadata
TitlePregled farmakoekonomskih analiza terapije atopijskog dermatititsa
Title (english)Review of pharmacoeconomic analysis for atopic dermatitis therapy
AuthorElena Matas
MentorPetra Turčić (mentor)
Committee memberPetra Turčić (predsjednik povjerenstva)
Committee memberIvan Pepić (član povjerenstva)
Committee memberNives Pustišek (član povjerenstva)
GranterUniversity of Zagreb
Faculty of Pharmacy and Biochemistry
(Centre for applied pharmacy)
Zagreb
Defense date and country2019-09-30, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Pharmacy
Pharmacy
Abstract
AD je česta, kronična, recidivirajuća, upalna bolest kože koja se pojavljuje u osoba s atopijskom konstitucijom. Prevalencija je u djece 15 do 30%, a u odraslih 2 do 10%. AD je karakteriziran svrbežom, suhom kožom i crvenilom te je često udružen s drugim atopijskim bolestima kao što su alergija, astma i alergijski rinitis. Etiopatogeneza je složena i još nije u potpunosti razjašnjena. Klinička slika se može mijenjati od blagih do teških oblika bolesti. Dijagnoza se postavlja na temelju kliničke slike, a procjena bolesti određuje se prema standardiziranim kriterijima i testovima za procjenu težine bolesti. AD ne samo da utječe na kvalitetu života oboljelog i njegove obitelji, već je i teret za zdravstveni sustav. Zato se provode farmakoekonomske analize, kojima je cilj usporediti troškove i učinkovitost terapije te pronaći onu najisplativiju. U jednoj cost-effectiveness analizi dokazana je isplativost profilaktičkog nanošenja hidratacijskog sredstva na novorođenčad visokog rizika oboljevanja od AD-a. Niskim ulaganjem u hidratacijska sredstva prvih šest mjeseci života, smanjuje se pojavnost bolesti te posljedično manje pacijenta ima potrebu za skupocjenom terapijom u budućnosti. Kao najisplativija topikalna terapija smatra se upotreba topikalnih kortikosteroida, te se analizom troška i koristi (cost-utility analysis, CUI) dokazala prednost korištenja topikalnih kortikosteroida u odnosu na inhibitore kalcineurina (pimekrolimus) jer terapija košta manje i učinkovitija je. Ako se nefarmakološke mjere i topikalna terapija pokažu neuspješnima, u terapiju se uvodi ciklosporin A ili UVAB fototerapija. Analizom troška i učinkovitosti dokazana je prednost korištenja ciklosporina A u odnosu na UVAB fototerapiju zbog velike količine vremena utrošenog u odlaske na mjesta gdje se nalazi uređaj za fototerapiju. U liječenju AD-a , kao najnovija skupina lijekova, počinju se primjenjivati biološki lijekovi. Ekonomskom analizom procijenjena je cijena dupilumaba, ovisna o vrijednosti, koja se smatra isplativom u odnosu na potpornu terapiju (emolijense) te je dokazano da za prag potrošnje od 100000-15000$/QALY godišnja potrošnja dupilumaba mora biti između 29000-40000$ da bi se terapija smatrala isplativom.
Abstract (english)
Atopic dermatitisis a common, chronic, recurrent, inflammatory skin disease that occurs in people with atopic constitution. Prevalence is 15 to 30% in children and 2 to 10% in adults. Atopic dermatitis is characterized by itching, dry skin and redness, and is often associated with other atopic diseases such as food allergy, asthma and allergic rhinitis. Etiopathogenesis is complex and not fully understood. The clinical picture may change from mild to severe type of atopic dermatitis. The diagnosis is made on the basis of clinical images, and the disease is determined according to standardized criteria and tests for the evaluation of diseases. Atopic dermatitis does not only affect the quality of life of the patient and his family, but is also an economic burden on the health system. Pharmacoeconomic analyzes are conducted to find the most cost-effective therapy. Studies suggest that prophylactic moisturization of high-risk newborns was cost-effective. Therefore, this type of low-cost intervention after birth (first six months) reduce the incidence of the disease and it is possible that fewer patients will require more expensive therapy in the future. The most cost-effective topical therapy are topical corticosteroids, and a cost-utility analysis has shown that topical corticosteroids are more cost-effective over calcineurin inhibitors (pimecrolymus). If non-pharmacological measures and topical therapy prove unsuccessful, cyclosporin A or UVAB phototherapy is administered. Cyclosporin A compares favorably with UVAB in term of cost-effectiveness because of time-consuming nature of UVAB phototherapy. The newest group of drugs in treatment of atopic dermatitis are biological drugs. Economic evaluation of dupilumab versus supportive therapy (emollients) reported that dupilumab is cost-effective at an annual price range of 29000-40000$ at the 100000- 150000$/QALY threshold range.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:163:525960
Study programmeTitle: Pharmacy
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: magistar/magistra farmacije (magistar/magistra farmacije)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2020-02-21 13:17:55